Clinical Trials Logo

Filter by:
NCT ID: NCT05344287 Completed - Hypertension Clinical Trials

Impact of a Plant-Based Diet on Indices of Cardiovascular Health in African Americans

Start date: July 12, 2019
Phase:
Study type: Observational

The role of diet in preventing hypertension and cardiovascular diseases in African Americans, who have a much higher risk of developing these diseases, is not well understood. Therefore, this project will investigate whether African Americans following a 100% plant-based diet have more optimal blood pressure, vascular function, and blood lipid profiles, along with lower systemic inflammation relative to African Americans following a typical American diet.

NCT ID: NCT05344196 Completed - PreDiabetes Clinical Trials

Emotional Awareness and Expression Therapy for Prediabetes

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

This feasibility study seeks to develop and pilot test Emotional Awareness and Expression Therapy as a possible treatment for people with prediabetes.

NCT ID: NCT05344040 Completed - Multiple Sclerosis Clinical Trials

Remote Exercise Effects on Cognitive Processing Speed in Multiple Sclerosis: A Pilot Trial

REACT-MS
Start date: May 25, 2022
Phase: Early Phase 1
Study type: Interventional

Cognitive processing speed (CPS) impairment is prevalent, impactful, and poorly-managed in multiple sclerosis (MS). Upwards of 67% of patients present with MS-related CPS impairment, which is associated with poor everyday life outcomes. There are no FDA-approved pharmacological treatments for CPS impairment in MS. This landscape creates a critical public health and clinical crisis that underscores the importance of identifying efficacious approaches for managing CPS impairment in MS. We believe that aerobic exercise training represents a promising and powerful behavioral approach. This project involves a single-blind randomized controlled trial of 16-weeks of remotely-delivered and supported aerobic walking exercise training compared with an active control condition (remotely-delivered and supported stretching and toning activities) on CPS (assessed remotely) in 24 fully-ambulatory, but CPS-impaired persons with MS. This pilot trial will be conducted in a fully-remote fashion, such that there are no required in-person visits to Kessler Foundation. Participants (N=24) will initially undertake baseline assessments of CPS remotely via a HIPAA-compliant virtual platform (i.e., Zoom for Healthcare). This assessment will also serve as a screen for ensuring impaired CPS. At this virtual study visit, participants further will undergo a neuropsychological test of verbal learning and complete questionnaires assessing physical activity and MS symptoms via computer (REDCap). Following baseline, participants will be randomly assigned into the remotely-delivered and supported aerobic walking exercise training intervention condition (n=12) or remotely-delivered and supported attention and social contact control condition (n=12) using concealment. Both conditions will be administered remotely over 16-weeks via telerehabilitation by a postdoctoral behavior coach during scheduled calls. Participants will undertake aerobic walking exercise training or stretching-and-toning in the home/community. The exercise training intervention involves aerobic walking exercise training that is monitored by a waist-worn FitBit and follows prescriptive guidelines for aerobic exercise for persons with MS. The control condition involves stretching-and-toning based on a manual published by the National Multiple Sclerosis Society. Both conditions further involve one-on-one coaching, action-planning via calendars, logs for self-monitoring, and newsletters based on Social Cognitive Theory. After the 16-week exercise/control period, participants will undergo remote assessments of CPS and verbal learning (administered by a treatment-blinded assessor) as well as completion of questionnaires assessing physical activity and MS symptoms via REDCap. If successful, this RCT will provide preliminary data on the extent to which (a) remotely-delivered/supported aerobic walking ET results in significant CPS improvements in CPS-impaired persons with MS; and (b) the intervention results in increased physical activity relative to an active control in a cognitively-impaired cohort. These pilot data will be essential for supporting a large R01 application on a multi-site, effectiveness RCT in a nationwide sample of CPS-impaired persons with MS.

NCT ID: NCT05343624 Completed - Diabetes Mellitus Clinical Trials

Use of Continuous Glucose Monitors in Coronavirus Disease 2019 ICU and Potential Inpatient Settings

CGMCOV
Start date: June 18, 2020
Phase: N/A
Study type: Interventional

The objective of the study is to improve glycemic control in inpatient/ICU settings using real- time continuous glucose monitors (CGM) data for insulin titration. It may help reduce Coronavirus disease 2019 patient contact with healthcare workers as well.

NCT ID: NCT05343585 Completed - Clinical trials for Nutrition Assessment

Validity of an AI-based Program to Identify Foods and Estimate Food Portion Size

PortionSizeAI
Start date: April 27, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to test the accuracy of the Nutrition Artificial Intelligence in the Openfit app during meals in a controlled laboratory setting

NCT ID: NCT05343559 Completed - First Impressions Clinical Trials

First Impressions and Attractiveness Levels of Smiling Individuals With and Without a Mask

Start date: March 4, 2022
Phase:
Study type: Observational

Evaluation on the effects of smiling on first impressions and attractiveness with and without wearing a facial surgical mask.

NCT ID: NCT05343533 Completed - Depression Clinical Trials

Probiotic Administration on Mood

PAM
Start date: July 17, 2019
Phase: N/A
Study type: Interventional

Researchers are looking to examine the impact of probiotic administration on symptoms commonly associated with depression, anxiety, stress, sleep quality, and associated emotional responses in healthy men and women.

NCT ID: NCT05343494 Completed - PreDiabetes Clinical Trials

Maternal Health Diabetes Prevention Study

Start date: April 4, 2022
Phase: N/A
Study type: Interventional

The aim of this project is to use the Exploration, Preparation, Implementation, Sustainment (EPIS) framework to collect pilot data on the implementation of a Diabetes Prevention Program-like intervention in the Women, Infants, and Children (WIC) program.

NCT ID: NCT05343468 Completed - Quality of Life Clinical Trials

Life Skills Improved in Children With Down Syndrome After Using Assistive Technology

Start date: September 20, 2020
Phase: N/A
Study type: Interventional

Enhancing independence and quality of life are key modifiable outcomes that are short- and long-term goals for children with Down syndrome (DS) and for their parents. The study investigated the efficacy of assistive technology in improving children with Down Syndrome's independence and quality of life. Using a commercially available assistive technology, the MapHabit system, the investigators implemented the software with participants' families for 4 weeks. The investigators hypothesized that the assistive technology will improve adaptive behavioral skills and overall quality of life.

NCT ID: NCT05343455 Completed - Clinical trials for Papulopustular Rosacea

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

MVOR-2
Start date: March 29, 2022
Phase: Phase 3
Study type: Interventional

This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks. Of the 320 subjects, approximately 160 subjects are planned to be enrolled at 15 sites in the US, while the remaining subjects are to be enrolled at 14 sites in the EU.